{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T08:22:12Z","timestamp":1767687732467,"version":"3.48.0"},"reference-count":31,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therap Adv Gastroenterol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Data on direct and indirect annual costs for inflammatory bowel disease (IBD) patients treated with vedolizumab are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To evaluate the total annual direct healthcare costs and indirect costs among IBD patients treated with vedolizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>\n                      A prospective observational multicentre study involving 286 patients with Crohn\u2019s disease (CD;\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009169) or ulcerative colitis (UC;\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009117) who started vedolizumab therapy during 2015\u20132017 at 21 hospitals across Sweden.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Data on direct and indirect costs were collected during a 3-year follow-up period. Direct costs were measured as healthcare resource utilization including medication, hospital admissions and hospital-based outpatient visits. Indirect societal costs were measured as production losses from sick leave and disability pension. Data were obtained from the Swedish Quality Register for IBD and through linkage with national registers. Data are presented both for patients who continued treatment throughout the follow-up period and for patients who discontinued treatment (CD:\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200983; UC:\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200948).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The mean annual direct follow-up cost was \u20ac24,305 for all IBD patients, \u20ac24,873 for CD patients and \u20ac23,484 for UC patients (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.24). No difference was observed between men and women (\u20ac24,506 vs \u20ac24,080;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.87). Direct costs were similar in patients who continued vedolizumab for the entire study period (\u20ac24,401) and those who discontinued treatment (\u20ac24,192;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.12). Medication was the primary driver of direct costs (64%), followed by hospital admissions (19%) and outpatient care (17%). Mean indirect costs were lower among patients who continued vedolizumab (\u20ac3044) than among those who stopped the treatment (\u20ac8927;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Increased direct costs were associated with perianal disease and high baseline disease activity in CD, and concurrent use of immunomodulators in UC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Patients treated with vedolizumab in Swedish clinical practice represent a group with high direct costs, primarily due to medication expenses. However, indirect costs were significantly lower than in previous reports.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562848251352023","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T11:31:53Z","timestamp":1752751913000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Healthcare resource utilization and production loss in vedolizumab-treated inflammatory bowel disease patients: results from the Swedish prospective multicentre SVEAH study"],"prefix":"10.1177","volume":"18","author":[{"given":"Linda","family":"Ryen","sequence":"first","affiliation":[{"name":"University Health Care Research Center, Faculty of Medicine and Health, \u00d6rebro University, \u00d6rebro, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6316-5027","authenticated-orcid":false,"given":"Isabella","family":"Visuri","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine and Health, \u00d6rebro University, \u00d6rebro, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Karlqvist","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine and Health, \u00d6rebro University, \u00d6rebro, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Malmgren","sequence":"additional","affiliation":[{"name":"Takeda Pharma AB, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1906-0746","authenticated-orcid":false,"given":"Daniel","family":"Bergemalm","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine and Health, \u00d6rebro University, \u00d6rebro, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1046-383X","authenticated-orcid":false,"given":"Carl","family":"Eriksson","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine and Health, \u00d6rebro University, S\u00f6dra Grev Rosengatan, \u00d6rebro 70185, Sweden"},{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Almer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olof","family":"Grip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Marsal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"S\u00f6derman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Strid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-065186"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14268"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2014.07.006"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215734"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215739"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.05.008"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16445"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15889"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17932"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562848231174953"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39335.541782.AD"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2019.1660799"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-009-9350-y"},{"key":"e_1_3_4_16_2","unstructured":"Swedish National Board of Health and Welfare et al. Kvalitet och inneh\u00e5ll i patientregistret. Utskrivningar fr\u00e5n slutenv\u00e5rden 1964-2007 och bes\u00f6k i specialiserad \u00f6ppenv\u00e5rd (exklusive prim\u00e4rv\u00e5rdsbes\u00f6k) 1997-2007.(Quality and content of the Patient Register) (2009-125-15) https:\/\/www.socialstyrelsen.se\/contentassets\/12ab370b4cec441db1b8b0c78b9d6a1d\/2009-125-15_200912515_rev2.pdf (2009 accessed January 20 2025)."},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-11-450"},{"key":"e_1_3_4_18_2","unstructured":"Swedish Association of Local Authorities and Regions. National cost per patient principles https:\/\/skr.se\/download\/18.187235b2180b4dcf16ac5ae\/1652426603256\/SKR_A4_KPP-principer_Webb.pdf (2020 accessed January 20 2025)."},{"key":"e_1_3_4_19_2","unstructured":"Swedish National Board of Health and Welfare. DRG \u2013 basic concept and principles https:\/\/www.socialstyrelsen.se\/globalassets\/sharepoint-dokument\/dokument-webb\/klassifikationer-och-koder\/drg-grundlaggande-begrepp-och-principer.pdf (2022 accessed 20 January 2025)."},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1294"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-019-00511-8"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562848211023386"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17675"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529709002993"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.041616"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.05.052"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/2050640619853448"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-303376"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0142481"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168586"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20939"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-022-01444-y"}],"container-title":["Therapeutic Advances in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848251352023","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562848251352023","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848251352023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T08:17:44Z","timestamp":1767687464000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562848251352023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":31,"alternative-id":["10.1177\/17562848251352023"],"URL":"https:\/\/doi.org\/10.1177\/17562848251352023","relation":{},"ISSN":["1756-2848","1756-2848"],"issn-type":[{"type":"print","value":"1756-2848"},{"type":"electronic","value":"1756-2848"}],"subject":[],"published":{"date-parts":[[2025,7]]},"article-number":"17562848251352023"}}